Cargando…

MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4

ABSTRACT: BACKGROUND: Overexpression of microRNA-182 (miR-182) is found in various human cancers, including non-small cell lung cancer (NSCLC). Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. METHODS: TaqMan RT-PCR or Western blot assay was...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Fang-ling, Wang, Feng, Li, Mian-li, Yu, Ze-shun, Hao, Yan-zhang, Chen, Shao-shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108001/
https://www.ncbi.nlm.nih.gov/pubmed/25012722
http://dx.doi.org/10.1186/1746-1596-9-143
_version_ 1782327690339024896
author Ning, Fang-ling
Wang, Feng
Li, Mian-li
Yu, Ze-shun
Hao, Yan-zhang
Chen, Shao-shui
author_facet Ning, Fang-ling
Wang, Feng
Li, Mian-li
Yu, Ze-shun
Hao, Yan-zhang
Chen, Shao-shui
author_sort Ning, Fang-ling
collection PubMed
description ABSTRACT: BACKGROUND: Overexpression of microRNA-182 (miR-182) is found in various human cancers, including non-small cell lung cancer (NSCLC). Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. METHODS: TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-182 and programmed cell death 4 (PDCD4) protein. miR-182 and (or) PDCD4 depleted cell lines were generated using miR-182 inhibitor and (or) siRNA. The viabilities of treated cells were analyzed using MTT assay. RESULTS: The expression level of miR-182 in A549 cell line was significantly higher than that in NHBE cell line (p < 0.01). Transfection of miR-182 inhibitor induced sensitivity of A549 cells to cisplatin. A549 cells transfected with PDCD4 siRNA became more resistant to cisplatin therapy. We found an increase PDCD4 protein level following the transfection of miR-182 inhibitor using Western blot analysis. In addition, the enhanced growth-inhibitory effect by miR-182 inhibitor was weakened after the addition of PDCD4 siRNA. CONCLUSIONS: The results of the present study demonstrated that overexpression of miR-182 may involve in chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1793467320130186
format Online
Article
Text
id pubmed-4108001
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41080012014-07-24 MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4 Ning, Fang-ling Wang, Feng Li, Mian-li Yu, Ze-shun Hao, Yan-zhang Chen, Shao-shui Diagn Pathol Research ABSTRACT: BACKGROUND: Overexpression of microRNA-182 (miR-182) is found in various human cancers, including non-small cell lung cancer (NSCLC). Our aim is to investigate the association of miR-182 expression with the sensitivity of NSCLC to cisplatin. METHODS: TaqMan RT-PCR or Western blot assay was performed to detect the expression of mature miR-182 and programmed cell death 4 (PDCD4) protein. miR-182 and (or) PDCD4 depleted cell lines were generated using miR-182 inhibitor and (or) siRNA. The viabilities of treated cells were analyzed using MTT assay. RESULTS: The expression level of miR-182 in A549 cell line was significantly higher than that in NHBE cell line (p < 0.01). Transfection of miR-182 inhibitor induced sensitivity of A549 cells to cisplatin. A549 cells transfected with PDCD4 siRNA became more resistant to cisplatin therapy. We found an increase PDCD4 protein level following the transfection of miR-182 inhibitor using Western blot analysis. In addition, the enhanced growth-inhibitory effect by miR-182 inhibitor was weakened after the addition of PDCD4 siRNA. CONCLUSIONS: The results of the present study demonstrated that overexpression of miR-182 may involve in chemoresistance of NSCLC cells to cisplatin by down-regulating PDCD4. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1793467320130186 BioMed Central 2014-07-10 /pmc/articles/PMC4108001/ /pubmed/25012722 http://dx.doi.org/10.1186/1746-1596-9-143 Text en Copyright © 2014 Ning et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ning, Fang-ling
Wang, Feng
Li, Mian-li
Yu, Ze-shun
Hao, Yan-zhang
Chen, Shao-shui
MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title_full MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title_fullStr MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title_full_unstemmed MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title_short MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4
title_sort microrna-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting pdcd4
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108001/
https://www.ncbi.nlm.nih.gov/pubmed/25012722
http://dx.doi.org/10.1186/1746-1596-9-143
work_keys_str_mv AT ningfangling microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4
AT wangfeng microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4
AT limianli microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4
AT yuzeshun microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4
AT haoyanzhang microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4
AT chenshaoshui microrna182modulateschemosensitivityofhumannonsmallcelllungcancertocisplatinbytargetingpdcd4